Life Insurance Corporation of India Holds 4.32 Per Cent Stake: Leading Pharma company Commissions New Rs 205 Crore Manufacturing Facility At Pithampur
In the last 12 months, the stock is down by 8.99 per cent while from its 52-week low it is up by 20.7 per cent.
Alembic Pharmaceuticals Limited has announced the commissioning of a new manufacturing facility located at Pithampur, District Dhar, Madhya Pradesh. The announcement was made on April 26, 2025, in a notification to the Bombay Stock Exchange Limited (BSE) and the National Stock Exchange of India Ltd. (NSE). The new facility is designated for the manufacturing of formulations.
The company provided details of the new facility as per regulatory requirements. The existing capacity involves manufacturing for multiple formulations, and most of the existing facilities are optimally utilised. The proposed capacity utilization details were not applicable. The project has been completed, with the capacity addition already done. The investment in the new facility is approximately Rs 205 crore. The mode of financing for this expansion is through internal accruals and borrowings. The rationale behind the expansion is to grow the business and to move third-party products in-house.
DSIJ's ‘Mid Bridge’ service recommends well researched Mid-Cap stocks for smart investing. If this interests you, download the service details here.
In the Quarterly Results of December 2024, the company reported a revenue of Rs 1,692.74 crore, reflecting a YoY growth of 3.81 per cent compared to Rs 1,630.57 crore in December 2023. The operating profit stood at Rs 260.22 crore, marking a decline of 2.29 per cent from Rs 266.32 crore in the same quarter last year. The profit after tax (PAT) declined by 23.29 per cent to Rs 138.42 crore from Rs 180.45 crore in December 2023.
In FY24, the company posted a revenue of Rs 6,228.63 crore, registering a 10.19 per cent growth compared to Rs 5,652.62 crore in FY23. The net profit for the year stood at Rs 615.82 crore, up 80.07 per cent from Rs 341.99 crore in the previous financial year. The company has been maintaining a healthy dividend payout of 39.6 per cent. In the last 12 months, the stock is down by 8.99 per cent while from its 52-week low it is up by 20.7 per cent.
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of pharmaceutical products, i.e. Formulations and Active Pharmaceutical Ingredients.
The company has 3 R&D and 5 manufacturing facilities. Alembic is among the top 25 players in the domestic formulations market. The company has a portfolio of about 200 formulation brands, of which three are among the top 300 domestic formulation brands in India. It has a share of 1.5 per cent in the domestic market.
Investors should keep eye on this stock.
Disclaimer: The article is for informational purposes only and not investment advice.